We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort.
- Authors
Kann, Hanna; Lehtinen, Matti; Eriksson, Tiina; Surcel, Heljä-Marja; Dillner, Joakim; Faust, Helena
- Abstract
<bold>Background: </bold>Human papillomaviruses (HPV) cause several human cancers. Bivalent (Cervarix) and quadrivalent (qGardasil) HPV vaccines both contain virus-like particles of the major oncogenic HPV types 16 and 18, but also cross-protect against some nonvaccine types. However, data on long-term sustainability of the cross-reactive antibody responses to HPV vaccines are scarce.<bold>Methods: </bold>Serum samples donated 7-12 years after immunization at age 16-17 years with bivalent (n = 730) or quadrivalent (n = 337) HPV vaccine were retrieved from the population-based Finnish Maternity Cohort biobank. Serum antibody levels against HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 73 were determined using multiplex pseudovirion binding assay. Antibody avidity was assessed using ammonium thiocyanate treatment.<bold>Results: </bold>Seropositivity for HPV31, 33, 35, 45, 51, 52, 58, 59, 68, and 73 was increasingly common (P ≤ .001; χ 2 test for trend for each of these types) when women had high anti-HPV16 antibody levels. For 8 nonvaccine HPV types seropositivity was more common among recipients of bivalent than quadrivalent vaccine, in particular for HPV31, 35, 45, 51, 52, and 58 (P < .001). Antibody avidity was higher in the quadrivalent vaccine recipients for HPV6, 11, and two of the nonvaccine types, but lower for HPV16 and 18 (P < .001).<bold>Conclusions: </bold>Both vaccines elicit cross-reactive antibodies detectable even 12 years after vaccination. Cross-reactive seropositivity is more common in women with high anti-HPV16 antibody response and in the bivalent vaccine recipients.
- Subjects
FINLAND; HUMAN papillomavirus vaccines; ANTIBODY formation; BINDING site assay; PAPILLOMAVIRUSES; AMMONIUM thiocyanate; ANTIGEN-antibody reactions; RESEARCH; VERTEBRATES; IMMUNIZATION; RESEARCH methodology; EVALUATION research; COMBINED vaccines; COMPARATIVE studies; VIRUS diseases; PAPILLOMAVIRUS diseases; VIRAL antibodies; LONGITUDINAL method
- Publication
Journal of Infectious Diseases, 2021, Vol 223, Issue 11, p1992
- ISSN
0022-1899
- Publication type
journal article
- DOI
10.1093/infdis/jiaa617